Company Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.
Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.
Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
| Country | United States |
| IPO Date | Sep 17, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. David-Alexandre C. Gros M.D., Ph.D. |
Contact Details
Address: 19900 MacArthur Boulevard Irvine, California United States | |
| Website | https://eledon.com |
Stock Details
| Ticker Symbol | ELDN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404281 |
| CUSIP Number | 28617K101 |
| ISIN Number | US28617K1016 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | Chief Executive Officer & Non Independent Director |
| Paul Sean Little | Chief Financial Officer |
| Bryan E. Smith J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer |
| Dr. Eliezer Katz F.A.C.S., FACS, M.D. | Chief Medical Officer |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer & Non Independent Director |
| John Herberger | Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 05, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 05, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 31, 2024 | 4 | Filing |